PMRR-NO: Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide

Completed · Phase 2

Conditions studied: Gastrointestinal Disease, Esophageal Cancer, Lung Cancer

In brief

The goal of this clinical research study is to use a new breathing test that measures the amount of nitric oxide (NO) you exhale. Researchers want to compare your "NO" levels to the amount of inflammation in your lungs, as measured using a positron emission tomography (PET) scan reading, and with respiratory symptoms questionnaire.

Key facts

Study ID

NCT00867477

Run by

M.D. Anderson Cancer Center

People needed

163

Starts

2009-03-01

Expected to finish

2014-08-01

Last updated by the study team

2014-08-28

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with pathologic diagnosis of esophagus cancer.
• For the cohort 2, patients with the pathological diagnosis of lung cancer.
• For the cohort 3, patients with any pathological diagnosis of a thoracic malignancy.
• Patients must sign informed consent.
• Patients who will receive concurrent chemotherapy and radiation therapy will be undergoing PET-scan for restaging between 25 and 75 days after radio therapy.
• For Lung Cohort, patients who will receive concurrent chemotherapy and radiation therapy or greater or equal to 3 weeks of radiation therapy alone.
• For the Lung Cohort, participation in a PET-scan for restaging between 40-50 days after radiotherapy is required. 10 patients will receive a second PET-scan within 2-7 days as a test for reproducibility.

You may not qualify if…

• Significant pleural effusion as evaluated by the attending Radiation Oncologist is excluded.
• Patients who received thoracic radiotherapy prior to the study.

Where it is running

• UT MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.